SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced that REPEL-CV, the company’s bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery. REPEL-CV will be marketed throughout Russia by Cardiomedics, Ltd.
Home » SyntheMed Receives Russian Regulatory Approval For REPEL-CV(TM)
More recent news
- Medtronic Diabetes names CFO with consumer experience ahead of separation
- Preceptis Medical has a new CEO as it advances ear tube tech
- FDA clears first over-the-counter cuffless blood pressure monitor
- Mendaera wins FDA clearance for robotic needle placement
- Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
